Syncom Formul.
NSE: SYNCOMF · Pharmaceuticals
Snapshot
Unlock Syncom Formul.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Syncom Formulations (India) Limited is a pharmaceutical company that manufactures and markets a diverse range of generic formulations across various therapeutic categories. The company also engages in commodity trading and property rental activities, while maintaining an export presence alongside its domestic operations.
Business Model
The company generates revenue primarily through the manufacturing and sale of pharmaceutical dosage forms including tablets, capsules, injections, and syrups. It supplements its core pharmaceutical business with income from commodity trading and the leasing of commercial properties.
- Founded:1985
Growth Outlook
Growth is driven by the expansion of its extensive product portfolio across multiple therapeutic segments and the scaling of its export operations. The company continues to leverage its diverse manufacturing capabilities to cater to both domestic and international market demands.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations that can impact manufacturing operations and product approvals.
- Market Competition. The company faces intense competition from both large-scale pharmaceutical manufacturers and smaller generic players in the Indian market.
- Commodity Price Volatility. Exposure to commodity trading introduces risks related to price fluctuations and market demand for non-pharmaceutical goods.
- Export Dependency. Reliance on international markets exposes the company to currency exchange rate fluctuations and geopolitical trade barriers.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Syncom Formul. and 5,000+ companies — free.
Key Metrics
REVENUE
₹489 Cr
TTM · consolidated
NET PROFIT
₹76 Cr
TTM · consolidated
EPS
₹0.89
TTM · consolidated
RETURN ON EQUITY
21.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
27.4%
TTM · consolidated
P/E
15.4x
Q4 FY26 · consolidated
EV/EBITDA
11.8x
Q4 FY26 · consolidated
EBITDA MARGIN
22.2%
TTM · consolidated
NET PROFIT MARGIN
18.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Syncom Formul.SYNCOMF | 1,082 | 15.39 | 11.81 | 5.0% | 22.2% | 21.2% | 27.4% | -27.3% |
Hester BiosHESTERBIO | 1,150 | 36.08 | 23.45 | 6.9% | 29.0% | 17.6% | 15.2% | +31.0% |
Sakar HealthcareSAKAR | 1,148 | 65.52 | 28.44 | 41.8% | 28.3% | 10.3% | 13.3% | +148.6% |
Beta Drugs LtdBETA | 1,096 | — | — | — | 20.0% | — | — | +34.8% |
Kilitch DrugsKILITCH | 1,091 | 13.45 | 14.88 | 18.7% | 20.3% | 13.3% | 17.3% | -60.2% |
Bajaj HealthcareBAJAJHCARE | 1,040 | 54.68 | 12.96 | 12.6% | 18.3% | 3.3% | 9.0% | -28.9% |
As of Q4 FY26
Financials
Syncom Formul.
NSE: SYNCOMF · Pharmaceuticals
Snapshot
Unlock Syncom Formul.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Syncom Formulations (India) Limited is a pharmaceutical company that manufactures and markets a diverse range of generic formulations across various therapeutic categories. The company also engages in commodity trading and property rental activities, while maintaining an export presence alongside its domestic operations.
Business Model
The company generates revenue primarily through the manufacturing and sale of pharmaceutical dosage forms including tablets, capsules, injections, and syrups. It supplements its core pharmaceutical business with income from commodity trading and the leasing of commercial properties.
- Founded:1985
Growth Outlook
Growth is driven by the expansion of its extensive product portfolio across multiple therapeutic segments and the scaling of its export operations. The company continues to leverage its diverse manufacturing capabilities to cater to both domestic and international market demands.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations that can impact manufacturing operations and product approvals.
- Market Competition. The company faces intense competition from both large-scale pharmaceutical manufacturers and smaller generic players in the Indian market.
- Commodity Price Volatility. Exposure to commodity trading introduces risks related to price fluctuations and market demand for non-pharmaceutical goods.
- Export Dependency. Reliance on international markets exposes the company to currency exchange rate fluctuations and geopolitical trade barriers.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Syncom Formul. and 5,000+ companies — free.
Key Metrics
REVENUE
₹489 Cr
TTM · consolidated
NET PROFIT
₹76 Cr
TTM · consolidated
EPS
₹0.89
TTM · consolidated
RETURN ON EQUITY
21.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
27.4%
TTM · consolidated
P/E
15.4x
Q4 FY26 · consolidated
EV/EBITDA
11.8x
Q4 FY26 · consolidated
EBITDA MARGIN
22.2%
TTM · consolidated
NET PROFIT MARGIN
18.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26